MiNK TherapeuticsINKT +2.56%34 FCF Yield % is -11.11 as of Jun. 28, 2026. GuruFocus rates INKT with a GF Score™ of 34/100. The stock has 2 warning signs investors should review. Among 1,416 Biotechnology companies, MiNK Therapeutics ranks worse than 53.32% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
MiNK Therapeutics FCF Yield % Related Terms
MiNK Therapeutics FCF Yield % Historical Data
* Premium members only.
The historical data trend for MiNK Therapeutics's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, MiNK Therapeutics's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MiNK Therapeutics FCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, MiNK Therapeutics's FCF Yield % distribution charts can be found below:
* The bar in red indicates where MiNK Therapeutics's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MiNK Therapeutics (INKT) has a FCF Yield % of -11.11 as of Jun. 28, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on MiNK Therapeutics and its competitors. According to the industry distribution chart, MiNK Therapeutics ranks #755 out of 1416 companies in the Biotechnology industry, placing it in the top 53.3%.
Is MiNK Therapeutics' FCF Yield % too high?
MiNK Therapeutics' current FCF Yield % is -11.11. Based on the distribution chart, MiNK Therapeutics ranks #755 out of 1416 companies in the Biotechnology industry, which is below the industry midpoint. Overall, MiNK Therapeutics has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does MiNK Therapeutics' FCF Yield % compare to PDSB and PMVP?
According to the Biotechnology industry distribution chart, MiNK Therapeutics ranks #755 out of 1416 companies for FCF Yield %. This places MiNK Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Biotechnology company?
A good FCF Yield % depends on the Biotechnology industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on MiNK Therapeutics and its competitors. MiNK Therapeutics's current FCF Yield % is -11.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MiNK Therapeutics stock overvalued right now?
MiNK Therapeutics (INKT) has a current FCF Yield % of -11.11. The current FCF Yield % is -11.11. MiNK Therapeutics' overall GF Score™ is 34/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For MiNK Therapeutics (INKT), the current FCF Yield % is -11.11 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development and manufacturing of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells, and suppress graft-versus-host-disease. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. It operates its business in single segment.
34GF Score
Get the complete analysis for INKT
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
INKT has been successfully added to your 
